Proposal for Resveratrol

Overview of Therapeutic Candidate:
Resveratrol is a naturally occurring polyphenol originally isolated from the skin of grapes, berries, and several other plant sources. As a member of the polyphenolic compounds, it belongs to a class of natural substances that have been extensively studied for their antioxidant properties and potential lifespan‐extending effects. Resveratrol was initially discovered in the context of the “French Paradox” and has since been synthesized and isolated in pure form (Sigma #R5010). Its chemical structure enables it to function as a potent antioxidant and a specific activator of SIRT1—a NAD⁺‐dependent deacetylase that plays an essential role in regulating cellular metabolism, mitochondrial biogenesis, and stress responses (Ege et al., 2024, pp. 14–16). Polyphenols in this class have historically been used as dietary supplements for their purported anti-aging and metabolic benefits, and several preclinical studies across varied models have indicated that compounds similar to resveratrol can mitigate oxidative damage and improve cell survival in tissues with high metabolic demands (Ege et al., 2024, pp. 2–3).

Therapeutic History:
Over the past two decades, resveratrol has been the subject of extensive biochemical and preclinical research due to its capacity to modulate multiple longevity-associated pathways. It has been used in a variety of experimental settings ranging from in vitro cell culture assays to in vivo rodent studies evaluating neurodegenerative disorders, cardiovascular diseases, and metabolic syndromes. In these studies, resveratrol demonstrated a favorable safety profile, with doses around 100 mg/kg in rodents resulting in significant activation of SIRT1 and subsequent modulation of downstream pathways such as the deacetylation of PGC-1α, thereby enhancing mitochondrial biogenesis (Ege et al., 2024, pp. 26–27; Muderris et al., 2022, pp. 1–2). Additionally, several animal models of acute ototoxicity and noise-induced hearing loss have shown that resveratrol administration can reduce auditory threshold shifts and attenuate cochlear degeneration by reducing oxidative stress and modulating apoptotic markers (Muderris et al., 2022, pp. 3–5; Lee et al., 2020, pp. 11–12). Although direct clinical trial evidence for resveratrol in the treatment of Age-Related Hearing Loss (ARHL) is lacking—as indicated by the current status in clinical trials (ClinicalTrials.gov, n.d.)—its promising effects in preclinical models of cochlear damage and related degenerative processes serve as a strong rationale for repurposing this drug candidate for ARHL.

Mechanism of Action:
The proposed mechanism of action for resveratrol in the context of ARHL centers on its ability to activate SIRT1 and function as an antioxidant. At the molecular level, resveratrol binds and activates SIRT1, which in turn deacetylates a number of transcription factors including PGC-1α, FOXO3a, and p53. Deacetylated PGC-1α becomes more active, leading to enhanced transcription of genes involved in mitochondrial biogenesis and oxidative phosphorylation (Ege et al., 2024, pp. 11–13; Takumida et al., 2016, pp. 11–12). This activation is critical because mitochondrial dysfunction and reduced cellular energy production have been identified as key contributors to ARHL, particularly in highly metabolically active cochlear hair cells (Ege et al., 2024, pp. 2–3). By stimulating mitochondrial biogenesis, resveratrol helps maintain cellular ATP levels and reduces the accumulation of damaged mitochondria, which in turn lowers the production of reactive oxygen species (ROS). As ROS mediate oxidative stress that damages cellular membranes, DNA, and proteins—including critical cytoskeletal elements in the hair cells—resveratrol’s antioxidant properties help to scavenge free radicals and prevent lipid peroxidation (Ege et al., 2024, pp. 26–27; Hu et al., 2023, pp. 21–22). Furthermore, resveratrol downregulates pro-apoptotic genes (e.g., Bax, Bak) while upregulating anti-apoptotic genes (e.g., Bcl-2, Bcl-xL), thereby reducing cellular apoptosis in the cochlea (Muderris et al., 2022, pp. 5–7). Through these dual actions—enhancing mitochondrial function and reducing oxidative damage—resveratrol is postulated to stabilize cytoskeletal proteins in cochlear hair cells, thereby preserving mechanotransduction efficiency (Ege et al., 2024, pp. 17–18). This cascade of events provides a robust protective effect against the deteriorative processes associated with ARHL.

Expected Effect:
Based on the mechanistic insights garnered from preclinical studies, the expected effect of resveratrol in an in vivo model of ARHL is multifaceted. Firstly, by activating SIRT1, resveratrol is anticipated to upregulate PGC-1α, which enhances mitochondrial biogenesis and maintains mitochondrial integrity in cochlear hair cells. This improvement in mitochondrial function is expected to reduce the overall levels of ROS and counteract the cumulative oxidative damage typically seen in aged cochlear cells (Ege et al., 2024, pp. 22–24; Xu & Yang, 2024, pp. 2–4). Secondly, due to its antioxidant properties, resveratrol should directly neutralize ROS, thereby mitigating oxidative stress that contributes to cellular senescence and apoptotic pathway activation within the cochlea (Hu et al., 2023, pp. 6–7; Saidia et al., 2024, pp. 15–17). Thirdly, by reducing oxidative stress and apoptosis, resveratrol is likely to confer indirect stabilization of cytoskeletal proteins, which are essential for preserving the structural integrity of hair cells and ensuring the proper gating of mechanotransduction (MET) channels (Ege et al., 2024, pp. 26–27; Xu & Yang, 2024, pp. 7–8). The combined effect is expected to result in the preservation of cochlear hair cell function and a slowing of the progression of hearing loss. Moreover, prior studies focusing on similar compounds have shown that maintenance of cytoskeletal integrity helps sustain ion channel function and proper cellular signaling essential for auditory transduction (Takumida et al., 2016, pp. 8–11). The confirmation of SIRT1 and PGC-1α expression in cochlear cells further supports the notion that these cells are responsive to resveratrol-mediated modulation of gene expression pathways critical to mitochondrial and cytoskeletal homeostasis.

Overall Evaluation:
Resveratrol stands out as a promising therapeutic candidate for ARHL due to several converging lines of evidence. Its natural origin and extensive safety profile, as demonstrated in both preclinical studies and early-phase clinical investigations for other indications, offer significant advantages in terms of repurposing potential (Ege et al., 2024, pp. 14–16; Wang & Puel, 2020, pp. 12–14). The compound’s ability to activate SIRT1 and, therefore, promote mitochondrial biogenesis, reduce oxidative stress, and stabilize critical structural proteins in cochlear hair cells provides a strong mechanistic basis for its use in ARHL (Ege et al., 2024, pp. 11–13; Xu & Yang, 2024, pp. 4–6). Resveratrol’s multi-targeted actions—spanning antioxidation, anti-inflammation, and anti-apoptosis—address several of the key pathophysiological mechanisms that contribute to hearing loss in aging populations (Muderris et al., 2022, p. 7; Xu et al., 2023, p. 23).

However, several challenges remain. One major limitation is the current lack of direct clinical evidence supporting its efficacy in ARHL, as indicated by the absence of registered clinical trials explicitly evaluating resveratrol for hearing loss (ClinicalTrials.gov, n.d.). Additionally, the compound’s bioavailability issues have been well documented in the literature, and achieving sufficient concentrations in the inner ear may require optimized dosing strategies or novel drug delivery systems (Lee et al., 2020, p. 12). The potential for a narrow therapeutic window, where low doses are beneficial but higher doses may be ineffective or even deleterious, further underscores the need for precise pharmacokinetic and pharmacodynamic characterization in the context of cochlear applications (Lee et al., 2020, pp. 11–12).

Despite these challenges, the strengths of resveratrol—including its robust preclinical data in models relevant to ARHL, its extensive history as an anti-aging and antioxidant agent, and its multi-modal mechanism of action—support its continued investigation as a candidate for repurposing in the treatment of ARHL. Future research should focus on addressing formulation and dosing challenges through advanced delivery methods, such as targeted nanoparticles or controlled-release systems, and on performing further in vivo studies in relevant animal models to validate its efficacy in stabilizing cochlear hair cell cytoskeletal structures and preserving auditory function (Ege et al., 2024, pp. 16–17; Tan et al., 2023, pp. 16–17).

In summary, resveratrol offers considerable promise as a therapeutic candidate for Age-Related Hearing Loss. Its ability to activate SIRT1 and stimulate the mitochondrial biogenesis pathway, coupled with its direct antioxidant actions that reduce ROS-induced damage, lays a solid foundation for its potential to stabilize cytoskeletal proteins and preserve mechanotransduction in cochlear hair cells. While further research, particularly translational studies and clinical trials, remains necessary to overcome existing bioavailability challenges and to validate the optimal dosing regimens, the current body of evidence supports continued development of resveratrol as a repurposed drug candidate for ARHL (Ege et al., 2024, pp. 24–25; Xu et al., 2023, pp. 4–6; Wang & Puel, 2020, pp. 18–19).

References
ClinicalTrials.gov. (n.d.). Resveratrol and hearing loss. Retrieved from https://clinicaltrials.gov/ct2/results?cond=&term=resveratrol+hearing+loss

Ege, T., Tao, L., & North, B. J. (2024). The role of molecular and cellular aging pathways on age-related hearing loss. International Journal of Molecular Sciences, 25, 9705. https://doi.org/10.3390/ijms25179705

Hu, S., Sun, Q., Xu, F., Jiang, N., & Gao, J. (2023). Age-related hearing loss and its potential drug candidates: A systematic review. Chinese Medicine. https://doi.org/10.1186/s13020-023-00825-6

Lee, C. H., Kim, K. W., Lee, S. M., & Kim, S. Y. (2020). Dose-dependent effects of resveratrol on cisplatin-induced hearing loss. International Journal of Molecular Sciences, 22, 113. https://doi.org/10.3390/ijms22010113

Muderris, T., Yar Sağlam, A. S., Unsal, D., Mülazımoğlu, S., Sevil, E., & Kayhan, H. (2022). Efficiency of resveratrol in the prevention and treatment of age-related hearing loss. Experimental and Therapeutic Medicine, 23, 40. https://doi.org/10.3892/etm.2021.10962

Saidia, A. R., François, F., Casas, F., Mechaly, I., Venteo, S., Veechi, J. T., Ruel, J., Puel, J.-L., & Wang, J. (2024). Oxidative stress plays an important role in glutamatergic excitotoxicity-induced cochlear synaptopathy: Implication for therapeutic molecules screening. Antioxidants, 13, 149. https://doi.org/10.3390/antiox13020149

Takumida, M., Takumida, H., Katagiri, Y., & Anniko, M. (2016). Localization of sirtuins (SIRT1-7) in the aged mouse inner ear. Acta Oto-Laryngologica, 136, 120–131. https://doi.org/10.3109/00016489.2015.1093172

Tan, J. T., Santos-Sacchi, J., Tonello, J., Shanker, A., & Ivanova, A. V. (2023). Pharmacological modulation of energy and metabolic pathways protects hearing in the FUS1/TUSC2 knockout model of mitochondrial dysfunction and oxidative stress. Antioxidants. https://doi.org/10.3390/antiox12061225

Wang, J., & Puel, J.-L. (2020). Presbycusis: An update on cochlear mechanisms and therapies. Journal of Clinical Medicine, 9, 218. https://doi.org/10.3390/jcm9010218

Xu, K., Xu, B., Gu, J., Wang, X., Yu, D., & Chen, Y. (2023). Intrinsic mechanism and pharmacologic treatments of noise-induced hearing loss. Theranostics, 13, 3524–3549. https://doi.org/10.7150/thno.83383

Xu, S., & Yang, N. (2024). The role and research progress of mitochondria in sensorineural hearing loss. Molecular Neurobiology. https://doi.org/10.1007/s12035-024-04470-4
